May 18, 2018 / 5:04 AM / 3 months ago

BRIEF-Cosmo Pharmaceuticals: FDA Accepts New Drug Application Submission For Rifamycin SV MMX

Reuters Staff

1 Min Read

May 18 (Reuters) - Cosmo Pharmaceuticals NV:

* FDA ACCEPTS NEW DRUG APPLICATION SUBMISSION FOR RIFAMYCIN SV MMX AND SETS PDUFA DATE FOR NOVEMBER 16, 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.

0 : 0

narrow-browser-and-phone
medium-browser-and-portrait-tablet
landscape-tablet
medium-wide-browser
wide-browser-and-larger
medium-browser-and-landscape-tablet
medium-wide-browser-and-larger
above-phone
portrait-tablet-and-above
above-portrait-tablet
landscape-tablet-and-above
landscape-tablet-and-medium-wide-browser
portrait-tablet-and-below
landscape-tablet-and-below